SparingVision raises $52M to kick off long journey for a next-gen gene therapy that goes much, much broader than Luxturna
21/10/2020
Until Spark Therapeutics’ pioneering gene therapy, Luxturna, came along, patients with retinitis pigmentosa had few [...]